The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells

Nearly half of human cancers harbor p53 mutations, and mutant p53 (mutp53) promotes carcinogenesis, metastasis, tumor recurrence and chemoresistance. mutp53 is observed in 30% of breast carcinomas, including triple‐negative breast cancer (TNBC), and thus mutp53 is a promising target for treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Jiajing, Xia, Jingruo, Zou, Jiang, Wang, Qiang, Ma, Qiang, Sun, Ru, Liao, Hebin, Xu, Lei, Wang, Dongsheng, Guo, Xiaolan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137801/
https://www.ncbi.nlm.nih.gov/pubmed/32027103
http://dx.doi.org/10.1002/2211-5463.12806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137801/
https://www.ncbi.nlm.nih.gov/pubmed/32027103
http://dx.doi.org/10.1002/2211-5463.12806

Ejemplares similares